Viking Therapeutics’ Weight Loss pill Shows Promising Results in Phase 2 Trial
Table of Contents
August 19, 2025 – Viking Therapeutics, a U.S.-based biopharmaceutical company,today announced positive topline results from its Phase 2 clinical study evaluating VK2735,an investigational oral weight loss medication.Teh findings demonstrate statistically significant reductions in body weight among participants receiving the drug, offering a potential new avenue for treating obesity and related metabolic disorders.
VK2735 Demonstrates Significant Weight loss
The Phase 2 trial assessed the efficacy and safety of VK2735 administered in oral tablet form. Participants who took daily doses of VK2735 experienced an average body weight reduction of up to 12.2% after thirteen weeks. Notably, the weight loss observed in the VK2735 groups was statistically significant compared to the placebo group, which saw an average reduction of up to 10.9%.
These results build upon previous studies indicating a dose-dependent response and substantial weight loss potential with VK2735. The drug’s mechanism of action targets specific receptors involved in regulating appetite and metabolism,possibly offering a more targeted approach to weight management than existing therapies. Research on receptor-targeted therapies highlights the growing interest in this field.
Did You know? Obesity is a global health crisis, affecting over 650 million adults worldwide, according to the World Health Institution.
Safety and Tolerability Profile
The study also evaluated the safety and tolerability of VK2735. While discontinuation rates due to adverse events were slightly higher in the VK2735 groups (28%) compared to the placebo group (18%), they were considered “low and well balanced.” The most frequently reported reason for discontinuing treatment was gastrointestinal discomfort.
Brian Lian, CEO of Viking Therapeutics, expressed enthusiasm about the findings. We are thrilled to present the main results of the phase 2 study on the oral monogyornal tablet of VK2735. As in previous studies, we observed a clear response to the dose and an impressive weight loss during the 13-week treatment period.
Lian further noted the potential for sustained weight management with longer-term dosing and a strategic approach to transitioning patients to lower oral doses after initial treatment.
Key Trial Data
| Metric | Placebo Group | VK2735 Group (Max Reduction) |
|---|---|---|
| Average Weight Loss (after 13 weeks) | Up to 10.9% | Up to 12.2% |
| Discontinuation Rate (Adverse Events) | 18% | 28% |
| Most Common Adverse Event | N/A | Gastrointestinal Discomfort |
The company is now planning further studies to explore the long-term efficacy and safety of VK2735, and also to optimize dosing strategies for both weight loss and maintainance. Will these results translate into a viable long-term solution for obesity?
Pro Tip: Maintaining weight loss often requires a multifaceted approach, including lifestyle modifications such as diet and exercise, alongside pharmacological interventions.
Looking Ahead: The Future of Obesity Treatment
The advancement of oral weight loss medications like VK2735 represents a significant step forward in addressing the obesity epidemic. Current treatment options frequently enough involve injectable medications or invasive procedures, limiting accessibility and patient adherence. A convenient oral formulation could potentially broaden access to effective weight management therapies. The success of VK2735 could pave the way for a new generation of targeted therapies designed to combat metabolic disorders. The CDC provides thorough information on obesity prevention and treatment.
The global obesity crisis continues to escalate,driven by factors such as sedentary lifestyles and readily available,calorie-dense foods. Research into novel therapeutic targets and drug delivery systems is crucial for developing effective and sustainable solutions. The focus is shifting towards personalized medicine, tailoring treatment approaches to individual patient characteristics and metabolic profiles. The long-term impact of VK2735 and similar drugs will depend on their ability to demonstrate sustained weight loss, improve metabolic health, and minimize adverse effects.
Frequently Asked Questions about VK2735
- What is VK2735? VK2735 is an experimental oral medication developed by Viking Therapeutics for the treatment of obesity.
- How much weight loss was observed in the Phase 2 trial? Participants taking VK2735 experienced an average weight loss of up to 12.2% after 13 weeks.
- What were the most common side effects of VK2735? The most common side effect reported was gastrointestinal discomfort.
- is VK2735 currently available? No, VK2735 is still in the clinical trial phase and is not yet available for public use.
- What is the next step in the development of VK2735? Viking Therapeutics plans to conduct further studies to assess the long-term efficacy and safety of the drug.
We invite you to share this article with your network and join the conversation in the comments below. Don’t forget to subscribe to our newsletter for the latest updates on medical breakthroughs and health news.
